Surrozen (SRZN) opened 2026 with Q1 revenue of about US$5 million and a basic EPS loss of roughly US$11.65 per share, while trailing twelve month figures show revenue of about US$7.49 million and a basic EPS loss of around US$36.80. Over recent quarters the company has seen quarterly revenue range from roughly US$0.53 million to US$5 million, with basic EPS swinging between a profit of about US$3.44 per share and losses that reached roughly US$20.09 per share. This context may help frame how you think about the current margin profile and potential directions it might take.

See our full analysis for Surrozen.

With the latest results on the table, the next step is to compare these margins and headline trends with the strongest stories investors already have in mind about Surrozen, and to consider which of those narratives the numbers actually support.

Losses remain heavy at US$127.5 million this quarter

• Q1 2026 net loss reached about US$127.5 million compared with a loss of roughly US$183.2 million in Q4 2025 and US$71.6 million in Q3 2025, while trailing twelve month losses came to around US$342.6 million.
• Bears focus on the company being unprofitable, and the trailing figures support that concern, with losses growing at an annualized rate of 36.9% over the past five years and trailing twelve month basic EPS at a loss of about US$36.80 per share.
  • That loss trend is reinforced by quarterly basic EPS, which was a loss of roughly US$11.65 in Q1 2026 after a loss of around US$20.09 in Q4 2025 and US$8.36 in Q3 2025.
  • The trailing twelve month net loss of approximately US$342.6 million, compared with US$242.0 million a year earlier, aligns with the bearish concern that losses have widened over time.

Revenue at US$5 million but forecasts flag a future decline

• Q1 2026 revenue of about US$5 million sits against trailing twelve month revenue of roughly US$7.5 million, while forecasts in the input point to an expected annualized revenue decline of 46.7% over the next three years.
• Critics highlight that an expected multi year revenue decline weighs on the story, and the data here back that, with the latest twelve month revenue of around US$7.5 million down from US$10.7 million in the twelve months to Q4 2024 and forecast revenue projected to fall further at a 46.7% annualized rate.
  • The quarterly pattern shows revenue moving between roughly US$0.53 million and US$5 million over the last six reported quarters, which limits support for a straightforward bullish growth argument.
  • Given the combination of small absolute revenue and the forecast decline cited in the input, the bearish view that investors may focus more on cash runway and dilution risk finds support in these numbers.

High P/S at 47.1x against losses and dilution

• The stock trades on a trailing P/S of 47.1x, compared with about 10.9x for the broader US Biotechs industry and 147.7x for the peer group, while shareholders’ equity is negative and the company has seen substantial dilution over the past year.
• A more optimistic take points to analyst price targets of US$40.75 versus the current share price of US$30.75, and that 32.5% implied upside sits in tension with the elevated P/S multiple of 47.1x and negative equity position.
  • On one hand, the higher P/S than the industry average of 10.9x can be read as investors already paying up relative to many US biotech stocks.
  • On the other hand, the stock trades below analyst targets at US$40.75, so the bullish view that there is room for re rating is anchored in that gap despite ongoing losses and dilution.

To see how other investors connect these earnings, valuation metrics and risks into a single story, it can help to look at the wider range of shared views on the company.Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Surrozen's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Given this mix of concerns and optimism around Surrozen, it helps to look at the underlying data yourself, weigh the trade offs, and then act on your own judgment using the 1 key reward and 3 important warning signs.

See What Else Is Out There

Surrozen is contending with heavy and widening losses, small and forecast declining revenue, and an elevated P/S multiple alongside dilution and negative equity.

If that mix of risk and volatility feels uncomfortable, you can quickly shift focus toward companies with steadier fundamentals by checking out 72 resilient stocks with low risk scores today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.